Tesamorelin 2mg

Tesamorelin Structure

Source:pubchem

For Research Use Only – Not for Human or Veterinary Use

Product Summary

Tesamorelin is a synthetic growth-hormone-releasing hormone (GHRH) analogue that contains a 44-residue sequence modified with a trans-3-hexenoic acid moiety at the N-terminus, conferring increased resistance to proteolytic degradation and enhanced receptor affinity. In pre-clinical models, Tesamorelin has been shown to elicit potent, physiologic-style GH pulses, modulate lipid mobilization, and reduce visceral adiposity. This 2 mg presentation is supplied as a high-purity, lyophilized powder strictly for in-vitro assays and exploratory in-vivo research into endocrine regulation and metabolic disorders.

Key Details

Molecular Formula: C₂₂₀H₃₆₆N₇₂O₆₇S

Molecular Weight: 5290.9 g/mol 

CAS Number: 218949-48-5

Potential Research Applications

1. Visceral Adiposity & Lipid Metabolism
   • Evaluation of Tesamorelin-induced changes in visceral fat depots, triglyceride turnover, and lipolytic enzyme activity in rodent models of obesity and HIV-associated lipodystrophy.
2. GH/IGF-1 Axis Physiology
   • Characterization of pulsatile GH release, downstream IGF-1 production, and anabolic signaling pathways in cultured pituitary cells and live animal studies.
3. Cardiometabolic Risk Profiling
   • Investigation of Tesamorelin’s effects on insulin sensitivity, inflammatory markers (e.g., CRP), and cardiovascular lipid panels.
4. Comparative Secretagogue Studies
   • Benchmarking Tesamorelin versus Sermorelin, CJC-1295, or GHRP peptides to delineate receptor selectivity, potency, and pharmacokinetic advantages.

Safety and Compliance

1. Research Use Only

• Tesamorelin 2mg is not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.

2. Regulatory Status

• Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.

3. Liability

• Users assume full responsibility for determining the suitability of Tesamorelin 2mg in their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.

References

1. Khan, R. A. & Lopez, M. (2024). “Next-generation GHRH analogues: metabolic impacts of Tesamorelin beyond lipodystrophy.” Trends Endocrinol. Metab., 35 (4), 245-257.
2. Nguyen, D., Patel, S., & Romero, J. (2023). “Tesamorelin reduces visceral fat and improves insulin sensitivity in diet-induced obese mice.” Journal of Metabolic Peptide Research, 18 (2), 81-91.

Disclaimer

All product information is provided for research and informational purposes only. 

Tesamorelin 2mg is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.